Brenner Randall B. 4
4 · Paratek Pharmaceuticals, Inc. · Filed Aug 10, 2023
Insider Transaction Report
Form 4
Brenner Randall B.
Chief Development & Regulatory
Transactions
- Award
Common Stock
2023-08-08+67,500→ 442,812 total - Sale
Common Stock
2023-08-09$2.20/sh−27,603$60,727→ 415,209 total
Footnotes (3)
- [F1]Represents performance-based restricted stock units ("PRSUs") granted on March 30, 2021 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on August 8, 2023.
- [F2]Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan adopted on May 26, 2021.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.19 to $2.21. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.